Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Autoimmune, and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PLCG2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | PLCG2 Full-Length Recombinant Protein (WT & clinical mutants e.g., R665W, L845F, C84W). High purity (>95%), Endotoxin <1EU/ug, HEK293 Expressed, Sequence Verified. | View PLCG2 Products |
| Gene Delivery | PLCG2 Promise-ORF Lentivirus. Full-length ORF for stable cell line generation. Puromycin selection available. | View PLCG2 Products |
| Benchmark Ab | Anti-PLCG2 Monoclonal Antibody (Research Grade). Recombinant positive control with high specificity for WB, IP. | View PLCG2 Products |
| Validator | PLCG2 siRNA Set (3 unique sequences). For knockdown verification and target specificity controls. | View PLCG2 Products |
| Related Target A | BTK (Bruton's Tyrosine Kinase). Upstream regulator; key resistance mechanism partner in B-cell malignancies. | View BTK Products |
| Related Target B | TREM2. Microglial receptor partner; crucial axis for Alzheimer's disease neuroinflammation. | View TREM2 Products |
| Related Target C | PLCG1 (Phospholipase C Gamma 1). Paralog for selectivity screening; critical off-target counter-screen. | View PLCG1 Products |
| Related Target D | BLNK (B-Cell Linker). Adaptor protein in BCR-PLCG2 signaling axis. | View BLNK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| BTK Inhibitor Resistance Screening | Sequence Verified clinical resistance mutations (R665W, L845F, C84W) proteins available with >95% purity. |
| Paralog Selectivity (PLCG1 vs PLCG2) | Human PLCG1 & PLCG2 proteins pair available; Sequence Verified; >95% purity for accurate IC50 determination. |
| Enzymatic Activity & Selectivity | Homolog panel (PLCG1/PLCG2) strictly verified by mass spec; native-folded high-purity proteins for IP3/Lipid hydrolysis assays. |
| Intracellular Target Engagement | High-purity antigens for biochemical assays; Endotoxin <1EU/ug; Theoretical MW verified for cellular assays. |
| Lack of Controls & False Positives | Validated siRNA set for cellular specificity checks; Clinical Benchmark Antibodies for assay standardization. |
Live PLCG2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PLCG2 therapeutics is intensifying, with major players shifting focus from traditional BTK inhibition to downstream signaling modulation. As first-generation BTK inhibitors drive acquired resistance mutations in PLCG2 (such as R665W), the next wave of R&D is heavily targeting mutant-specific PLCG2 degraders and allosteric modulators. Additionally, protective variants like PLCG2 P522R have positioned this enzyme as a breakthrough target for Alzheimer's disease, necessitating both high-purity wild-type and mutant recombinant proteins. In parallel, autoimmune indications such as APLAID syndrome represent a growing area for precision PLCG2 inhibitors. Both oncology (B-cell malignancies, leukemia) and neurodegeneration pipelines demand high-quality reagents for complex enzymatic and cellular assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitor/Allosteric) | Novartis, Merck, Various Oncology Biotechs | CLL, MCL (BTKi Relapsed), APLAID | Selectivity Assay (Need Sequence Verified Mutant vs WT Proteins) |
| Small Molecule (Activator) | Neurodegeneration Startups, Biogen | Alzheimer's Disease | Enzymatic Activity (Need Native-folded, High-Purity Proteins) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics, Nurix | Refractory B-Cell Lymphomas | Degradation Validation (siRNA for knockdown baseline; Ternary complex formation using high-purity PLCG2) |
| Inhibitor (Autoimmune) | Biogen, EMD Serono | APLAID, SLE | Enzymatic Activity Assay (IP3 detection; Purity critical) |